[Mirtazapine-associated hepatotoxicity].
Rodriguez-Pecci
María Soledad
MS
Fuente-Aguado
Javier de la
Jde L
Montero-Tinnirello
Javier
J
Fernandez-Fernandez
Francisco J
FJ
D000928:Antidepressive Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D002779:Cholestasis / Q000139:chemically induced*; D003866:Depressive Disorder / Q000150:complications / Q000188:drug therapy; D004347:Drug Interactions; D000068736:Duloxetine Hydrochloride; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000378:metabolism; D008297:Male; D008803:Mianserin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008875:Middle Aged; D000078785:Mirtazapine; D009400:Nephrosclerosis / Q000150:complications / Q000378:metabolism; D013876:Thiophenes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
D000928:Antidepressive Agents; D013876:Thiophenes; D008803:Mianserin; D000068736:Duloxetine Hydrochloride; D000078785:Mirtazapine